CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue	$ 841,661	$ 810,421	$ 2,538,756	$ 2,414,270
Cost of Revenue:
Cost of revenue	335,035	337,500	1,019,345	981,259
Gross profit	506,626	472,921	1,519,411	1,433,011
Expenses:
Sales and marketing	130,021	124,434	392,570	358,277
General and administrative	83,764	82,098	243,201	226,194
Research and development	48,013	40,427	211,402	115,703
Income from operations	244,828	225,962	672,238	732,837
Interest expense	(10,998)	(7,134)	(26,311)	(22,331)
Interest income	353	122	830	265
Income before provision for income taxes	234,183	218,950	646,757	710,771
Provision for income taxes	53,245	43,772	139,875	128,698
Net income	180,938	175,178	506,882	582,073
Less: Net loss attributable to noncontrolling interest	0	(57)	0	(1)
Net income attributable to IDEXX Laboratories, Inc. stockholders	$ 180,938	$ 175,235	$ 506,882	$ 582,074
Earnings per Share:
Basic (in USD per share)	$ 2.17	$ 2.06	$ 6.04	$ 6.82
Diluted (in USD per share)	$ 2.15	$ 2.03	$ 5.97	$ 6.71
Weighted Average Shares Outstanding:
Basic (in shares)	83,247	85,123	83,855	85,325
Diluted (in shares)	84,113	86,511	84,858	86,712
Product revenue
Revenue:
Total revenue	$ 481,004	$ 471,787	$ 1,451,899	$ 1,406,850
Cost of Revenue:
Cost of revenue	158,554	166,748	487,948	483,850
Service revenue
Revenue:
Total revenue	360,657	338,634	1,086,857	1,007,420
Cost of Revenue:
Cost of revenue	$ 176,481	$ 170,752	$ 531,397	$ 497,409